1, Myriad Medical, the first leading medical device stocks, the main life information and support. In vitro diagnostics, medical imaging three major areas, return on net assets to maintain more than 25%.
2, Hengrui medicine, domestic chemical innovation drug leader, the core products are anti-tumor, anesthesia, contrast agents.
3, WuXi AppTec, CRO + CDMO whole industry chain leader, is the most complete layout of the domestic new drug production outsourcing pharmaceutical enterprises, the main small molecule preclinical CRO + clinical CRO + small molecule drug CDMO.
4, Zhifei Biologicals, is one of the domestic new vaccine R & D pipeline reserves of the richest enterprises, mainly bacterial multiplexed multivalent vaccine products, viral vaccines products, tuberculosis control class three categories.
5, Aier Ophthalmology, the absolute leader in the field of ophthalmic services, the core business in the refractive, optometric services, cataract, and anterior and posterior segment of the eye and other businesses.
6, Pientzehuang, the leading domestic traditional Chinese medicine, Pientzehuang as liver disease, detoxification special effect medicine, unique in China.
7, Changchun High-Tech, the leader of recombinant life hormone, with growth hormone, vaccine and traditional Chinese medicine as the core business, the market share reaches 74%.
8, Yunnan Baiyao, one of the two major national Chinese medicine brands.
9, Tigermed, the leading clinical CRO with the deepest research and highest revenue in China.
10, Tongze medical, oral health care industry leader.